Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design
Quetiapine fumarate (QTF) was approved for the treatment of schizophrenia and acute manic episodes. QTF can also be used as an adjunctive treatment for major depressive disorders. QTF oral bioavailability is limited due to its poor aqueous solubility and pre-systemic metabolism. The objective of the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/3/324 |
| _version_ | 1827305322915561472 |
|---|---|
| author | Prateek Uttreja Ahmed Adel Ali Youssef Indrajeet Karnik Kavish Sanil Nagarjuna Narala Honghe Wang Rasha M. Elkanayati Sateesh Kumar Vemula Michael A. Repka |
| author_facet | Prateek Uttreja Ahmed Adel Ali Youssef Indrajeet Karnik Kavish Sanil Nagarjuna Narala Honghe Wang Rasha M. Elkanayati Sateesh Kumar Vemula Michael A. Repka |
| author_sort | Prateek Uttreja |
| collection | DOAJ |
| description | Quetiapine fumarate (QTF) was approved for the treatment of schizophrenia and acute manic episodes. QTF can also be used as an adjunctive treatment for major depressive disorders. QTF oral bioavailability is limited due to its poor aqueous solubility and pre-systemic metabolism. The objective of the current investigation was the formulation development and manufacturing of solid self-nanoemulsifying drug delivery system (S-SNEDDS) formulation through a single-step continuous hot-melt extrusion (HME) process to address these drawbacks. In this study, Capmul<sup>®</sup> MCM, Gelucire<sup>®</sup> 48/16, and propylene glycol were selected as oil, surfactant, and co-surfactant, respectively, for the preparation of S-SNEDDS. Soluplus<sup>®</sup> and Klucel™ EF (1:1) were selected as the solid carrier. Response surface methodology in the form of central composite design (CCD) was utilized in the current experimental design to develop the S-SNEDDS formulations via a continuous HME technology. The developed formulations were evaluated for self-emulsifying properties, particle size distribution, thermal behavior, crystallinity, morphology, physicochemical incompatibility, accelerated stability, and in vitro drug release studies. The globule size and emulsification time of the optimized SNEDDS formulation was 92.27 ± 3.4 nm and 3.4 ± 3.38 min. The differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) studies revealed the amorphous nature of the drug within the formulation. There were no drug-excipient incompatibilities observed following the Fourier transform infrared (FTIR) spectroscopy. The optimized formulation showed an extended-release profile for 24 h. The optimized formulation was stable for three months (last time-point tested) at 40 °C/75% RH. Therefore, the developed S-SNEDDS formulation could be an effective oral delivery platform for QTF and could lead to better therapeutic outcomes. |
| first_indexed | 2024-04-24T17:55:14Z |
| format | Article |
| id | doaj.art-98c7924a950b4c88abd6f53038b4ab0e |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-24T17:55:14Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-98c7924a950b4c88abd6f53038b4ab0e2024-03-27T13:59:36ZengMDPI AGPharmaceutics1999-49232024-02-0116332410.3390/pharmaceutics16030324Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite DesignPrateek Uttreja0Ahmed Adel Ali Youssef1Indrajeet Karnik2Kavish Sanil3Nagarjuna Narala4Honghe Wang5Rasha M. Elkanayati6Sateesh Kumar Vemula7Michael A. Repka8Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USADepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USAQuetiapine fumarate (QTF) was approved for the treatment of schizophrenia and acute manic episodes. QTF can also be used as an adjunctive treatment for major depressive disorders. QTF oral bioavailability is limited due to its poor aqueous solubility and pre-systemic metabolism. The objective of the current investigation was the formulation development and manufacturing of solid self-nanoemulsifying drug delivery system (S-SNEDDS) formulation through a single-step continuous hot-melt extrusion (HME) process to address these drawbacks. In this study, Capmul<sup>®</sup> MCM, Gelucire<sup>®</sup> 48/16, and propylene glycol were selected as oil, surfactant, and co-surfactant, respectively, for the preparation of S-SNEDDS. Soluplus<sup>®</sup> and Klucel™ EF (1:1) were selected as the solid carrier. Response surface methodology in the form of central composite design (CCD) was utilized in the current experimental design to develop the S-SNEDDS formulations via a continuous HME technology. The developed formulations were evaluated for self-emulsifying properties, particle size distribution, thermal behavior, crystallinity, morphology, physicochemical incompatibility, accelerated stability, and in vitro drug release studies. The globule size and emulsification time of the optimized SNEDDS formulation was 92.27 ± 3.4 nm and 3.4 ± 3.38 min. The differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) studies revealed the amorphous nature of the drug within the formulation. There were no drug-excipient incompatibilities observed following the Fourier transform infrared (FTIR) spectroscopy. The optimized formulation showed an extended-release profile for 24 h. The optimized formulation was stable for three months (last time-point tested) at 40 °C/75% RH. Therefore, the developed S-SNEDDS formulation could be an effective oral delivery platform for QTF and could lead to better therapeutic outcomes.https://www.mdpi.com/1999-4923/16/3/324quetiapine fumaratehot-melt extrusionself-nanoemulsifying drug delivery systemscentral composite design |
| spellingShingle | Prateek Uttreja Ahmed Adel Ali Youssef Indrajeet Karnik Kavish Sanil Nagarjuna Narala Honghe Wang Rasha M. Elkanayati Sateesh Kumar Vemula Michael A. Repka Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design Pharmaceutics quetiapine fumarate hot-melt extrusion self-nanoemulsifying drug delivery systems central composite design |
| title | Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design |
| title_full | Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design |
| title_fullStr | Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design |
| title_full_unstemmed | Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design |
| title_short | Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design |
| title_sort | formulation development of solid self nanoemulsifying drug delivery systems of quetiapine fumarate via hot melt extrusion technology optimization using central composite design |
| topic | quetiapine fumarate hot-melt extrusion self-nanoemulsifying drug delivery systems central composite design |
| url | https://www.mdpi.com/1999-4923/16/3/324 |
| work_keys_str_mv | AT prateekuttreja formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT ahmedadelaliyoussef formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT indrajeetkarnik formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT kavishsanil formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT nagarjunanarala formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT honghewang formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT rashamelkanayati formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT sateeshkumarvemula formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign AT michaelarepka formulationdevelopmentofsolidselfnanoemulsifyingdrugdeliverysystemsofquetiapinefumarateviahotmeltextrusiontechnologyoptimizationusingcentralcompositedesign |